Catheter-associated
urinary tract infections (CAUTIs)
frequently
occur following the insertion of catheters in hospitalized patients,
often leading to severe clinical complications. These complications
are exacerbated by biofilm-forming organisms such as
Staphylococcus aureus
, contributing to the emergence
of multidrug-resistant (MDR) strains, which complicates treatment
strategies. This study aims to investigate the antibacterial, antibiofilm,
and antiadhesive properties of duloxetine against
S.
aureus
in the context of CAUTI. Our findings demonstrate
that duloxetine exhibits significant antibacterial activity, as evidenced
by the agar diffusion method. A minimal inhibitory concentration (MIC)
of 37.5 μg/mL was established using the microdilution method.
Notably, duloxetine displayed inhibitory effects against biofilm formation
on polystyrene surfaces up to its MIC level, as demonstrated by the
crystal violet method. Intriguingly, the study also revealed that
duloxetine could prevent biofilm formation at lower concentrations
and reduce mature biofilms, as confirmed by scanning electron microscopy
(SEM) and quantitative biofilm assays. Furthermore, duloxetine-coated
silicone catheter tubes exhibited antibacterial properties against
S. aureus
in a bladder model, visualized by confocal
laser scanning microscopy (CLSM) and corroborated through FDA and
PI staining, highlighting noticeable morphological changes in
S. aureus
post-treatment. In conclusion, this study
presents duloxetine as a promising alternative agent with antibacterial
and antiadhesive properties against
S. aureus
in the prevention and management of CAUTI, warranting further exploration
in the clinical setting.